12,372 trials
Clostridium Difficile Infection (CDI)
Primary: Efficacy of RBX2660 Compared to Placebo Through 8 Weeks — 57.5; 70.6 Model-estimated percent of participants
Critical Limb Ischemia
Primary: Number of Participants With Primary Patency — 70; 38 Participants
Neuromyelitis Optica · Neuromyelitis Optica Spectrum Disorder
Primary: Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period — 0; 20 Participants — p=< 0.0001
Treatment Resistant Depression · Electroconvulsive Therapy · ECT
Primary: Number of Participants With Treatment Responses Based on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report Scale (QIDS-SR-16) — 70; 108 Participants…
Glaucoma and Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Week 1 — 19.4; 19.7; 18.5; 18.9 mmHg
Osteoarthritis, Knee
Primary: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score — -44.3; -37.5; -36.1 score on a scale — p=0.0406
Dim Light Vision Disturbances
Primary: Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye — 9; 2 Participants
COVID-19 Prevention
Primary: Groups 1 and 2: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibodies Against Each of the Four Influenza Vaccine Strains 28 Days After the…
Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoriasis
Primary: Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-safety Syringe (SS)-1mL or the Bimekizumab-auto-injector (AI)-1mL…
Meningococcal Vaccine
Primary: Stage1: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= Lower Limit of Quantitation (LLOQ) for All 4 Primary…
Growth Hormone Deficiency in Children
Primary: Height Velocity: In-trial Observation Period — 11.8; 11.2 centimeters per year (cm/year)
Virus Diseases · RNA Virus Infections · Respiratory Tract Infections
Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain — 603.7; 595.6; 630.6; 96.3 titers
HIV Infections
Primary: Number of Mother Participants With Serious Adverse Events (SAEs) Including Maternal Deaths in Both Study Arms — 2; 0 Participants
Respiratory Syncytial Virus Infections
Primary: Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single…
Cystic Fibrosis
Primary: Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48 — -35.0 milligrams per deciliter (mg/dl)